199167-79-8

Upstream product

• 2295-31-0 thiazoline-2,4-dione 
• 619-66-9 4-Carboxybenzaldehyde 
• 1571-08-0 methyl 4-formylbenzoate 
• 199167-77-6 4-(2,4-dioxothiazolidin-5-ylidenemethyl)benzoic acid methyl ester 

Downstream Products

• 371244-65-4 5-{4-[(R)-1-(2-benzoxazolyl)pyrrolidinyl-2-methoxycarbonyl]benzylidene}-thiazolidine-2,4-dione 
• 1373268-02-0 C₂₃H₂₃N₃O₄S 
• 1373268-06-4 C₂₉H₂₇N₃O₄S 
• 1373267-96-9 C₂₃H₂₃N₃O₅S 
• 1373268-04-2 C₂₆H₂₉N₃O₄S 
• 925556-13-4 4-((2, 4-dioxothiazolidin-5-ylidene)methyl)-N-(pyridin-2-yl)benzamide 
• 322415-41-8 4-((2,4-dioxothiazolidin-5-ylidene)methyl)-N-(thiazol-2-yl)benzamide 
• 942881-76-7 4-((2,4-dioxothiazolidin-5-ylidene)methyl)-N-(5-methylisoxazol-3-yl)benzamide 
• 635315-34-3 C₂₅H₂₅NO₆S 

Relevant academic research and scientific papers

Design, synthesis, and activity evaluation of GK/PPARγ Dual-target-directed ligands as hypoglycemic agents

Based on the multi-target strategy to treat type 2 diabetes mellitus (T2DM), glucokinase/peroxisome proliferator-activated receptor γ (GK/PPARγ) dual-target molecules were constructed by the rational combination of pharmacophores from known GK activators

5-Benzylidenerhodanine and 5-benzylidene-2-4-thiazolidinedione based antibacterials

Herein we outline the antibacterial activity of amino acid containing thiazolidinediones and rhodanines against Gram-positive bacteria Staphylococcus aureus ATCC 31890, Staphylococcus epidermidis and Bacillus subtilis ATCC 6633. The rhodanine derivatives

MATERIALS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA, AND ATHEROSCLEROSIS

The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is also drawn to methods of treating disorders, such as diabetes, comprising the administration of therapeutically effective compositions comprising compounds that have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester-containing thiazolidinedione analogs are also taught.

Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis

The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is also drawn to methods of treating disorders, such as diabetes, comprising the administration of therapeutically effective compositions comprising compounds that have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester-containing thiazolidinedione analogs are also taught.